Aktieanalys

Nolato: Thoughts on the GLP-1 potential - ABG

ABG Sundal Collier Publicerad: 13 Oct 2023 07:22

Escalating peer comments on GLP-1 obesity drugs
No comment yet from Nolato, but there are some clues
Speculative, but exciting given USD 100bn est. market size

News and peer comments about GLP-1 obesity drugs

Recently, we have noted an escalation of newsflow regarding supplier agreements for Novo Nordisk's GLP-1 obesity drug Wegovy from, among others, Ypsomed and Schott Pharma. In its most recent earnings call, peer Gerresheimer also commented that it has contracts with the leading GLP-1 players in place (see image below). The market for GLP-1 obesity drugs has been forecasted reach USD 100bn annual sales within a decade, with Novo Nordisk and Eli Lilly projected to be the market leaders.

Länk till analysen i sin helhet: https://cr.abgsc.com/foretag/nolato/Equity-research/2023/10/nolato---thouhgts-on-the-glp-1-potential/

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!